Gaucher disease: A current perspective

Khaled Saad[1]*, Hazem Mustafa Abdelall[2], Nahed Mohammed Abdelgabaar[3], Amira Elhoufey[4,5], Khalid Hashim Mahmoud[6]

1 Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt.
2 NMC Royal Hospital Abu Dhabi- UAE
3 Burjeel Hospital Abu Dhabi- UAE
4 Department of Community Health Nursing, Faculty of Nursing, Assiut University, Assiut, Egypt.
5 Department of Community Health Nursing, Alddrab University College, Jazan University, Jazan, Saudi Arabia.
6 Department of Pediatrics, Faculty of Medicine, Shaqra University, Dawadmi, Saudi Arabia.

*** Correspondence to:**
Professor Khaled Saad,
MD, PhD. Pediatric Department, Faculty of Medicine, Assiut University,71516 Assiut, Egypt.
Tel.: +201097075321, Email: khaled.ali@med.au.edu.eg.

Abstract:
Gaucher disease, a rare genetic disorder, has long been a subject of intrigue and investigation in the field of medical genetics. This paper offers a contemporary overview of Gaucher disease, shedding light on its pathogenesis, clinical manifestations, diagnostic approaches, and evolving therapeutic strategies. Gaucher disease, characterized by a deficiency of the enzyme glucocerebrosidase, leads to the accumulation of glucocerebroside within various tissues, resulting in a spectrum of clinical phenotypes. We delve into the intricacies of the disease's underlying genetics, exploring the diverse mutations that contribute to its heterogeneity. Clinical manifestations of Gaucher disease span a wide spectrum, encompassing hepatosplenomegaly, thrombocytopenia, and bone involvement. This paper comprehensively outlines the clinical presentation and the importance of early diagnosis in improving patient outcomes. Gaucher disease continues to intrigue researchers and clinicians alike, and this comprehensive overview aims to contribute to our collective understanding of this complex genetic disorder.

Keywords: Gaucher disease, Glucocerebrosidase, Enzyme replacement therapy, Substrate reduction therapy, Genetic disorder, Rare disease

INTRODUCTION

Gaucher disease (GD) is a hereditary metabolic disorder that disrupts the normal recycling process of glycolipids within cells. This condition stands out as one of the most prevalent among lysosomal storage diseases (1). Within the cellular lysosomes, a build-up occurs of substances like glucocerebroside (also known as glucosylceramide) and related compounds, which are typically broken down into glucose and lipid components. GD manifests in three clinical types, with type 1 (GD1, also known as MIM #230800) being the most commonly encountered. It can be differentiated from type 2 (GD2, also referred to as MIM #230900) and type 3 (GD3, with the designation MIM #231000) due to its notable absence of involvement in the central nervous system (CNS). Typically, GD affects visceral organs, bone marrow, and bones (1, 2). GD, a rare genetic disorder, has long been a subject of intrigue and investigation in the field of medical genetics. This

paper offers a contemporary overview of Gaucher disease, shedding light on its clinical manifestations, diagnostic approaches, and prognosis. Gaucher disease, characterized by a deficiency of the enzyme glucocerebrosidase, leads to the accumulation of glucocerebroside within various tissues, resulting in a spectrum of clinical phenotypes. We delve into the intricacies of the disease's underlying genetics, exploring the diverse mutations that contribute to its heterogeneity (1-3).

INITIAL ASSESSMENT

It is crucial for every patient to undergo a thorough initial evaluation of all potentially impacted organ systems. This step is essential because Gaucher disease (GD) can exhibit considerable diversity in its symptoms, severity, and progress, all of which can significantly influence treatment choices. The initial assessment encompasses confirming the deficiency of glucocerebrosidase enzyme (also known as glucosylceramidase or acid beta-glucosidase [GBA]), conducting genotyping, and, if these were not previously done as part of the diagnostic procedure, obtaining a comprehensive family medical history (1, 4).

Family history:

When assessing a patient's family history of GD, consider the following key details: Ethnic Background and Consanguinity: It is essential to gather information about the patient's ethnicity and whether there is consanguinity within the family. This is essential because GD follows an autosomal-recessive inheritance pattern, and specific variations of the disorder may be more prevalent in particular population groups. Disease History in Family Members: Document any history of GD in the patient's parents or affected siblings. Neurological Conditions: Inquire about the presence of Parkinson's disease or Lewy body dementia in the patient's parents, grandparents, or siblings, as there may be a connection. Medical History: Collect information related to blood transfusions, splenectomy (surgical removal of the spleen), pathologic fractures, bone pain, joint replacements, shortness of breath (dyspnea), bleeding tendencies, and perinatal deaths/hydrops fetalis in the family's medical history. The presence of any of these factors could indicate undiagnosed GD in a family member and provide insights into the potential severity of the disease (3, 4)."

Medical Examination:

A physical examination is crucial for assessing disease severity, progression rate, and treatment response. Key aspects of this examination include assessing the patient's overall appearance, mood, and demeanor. Measuring weight, height, and head circumference percentile according to age and gender on standardized growth charts. Inspecting the skin for signs like bruising, petechiae, pallor, and increased pigmentation, with a specific focus on neonates for ichthyosis. Palpating the abdomen for enlarged liver and spleen and measuring abdominal girth. Evaluating gait, joint mobility, muscle strength, and bone tenderness. Examining the spine for kyphosis and scoliosis (3, 4).

Neurological Assessment:

Prompt assessment of neurological complications is vital for prognosis and treatment planning, especially for patients with specific genetic profiles or symptoms. A thorough neurological evaluation for children should include: A neurological examination should be performed by a neurologist, preferably a pediatric specialist. Eye movement examination, ideally by an

ophthalmologist, as ocular signs can be challenging to detect in young children. Additional neuro-ophthalmological tests, such as direct ophthalmoscopy or electrooculography. Hearing tests, including otoacoustic emission audiometry (OAE) for young children and pure tone audiometry for older patients. Electroencephalography and diagnostic brainstem-evoked responses. Neurocognitive testing uses widely available protocols when the patient is healthy enough for meaningful assessment. Swallow evaluation through fluoroscopy for very young patients with choking or failure to thrive (3, 5, 6). Psychosocial Assessment: Evaluating a child's social and educational development may involve collaboration with schools and teachers. Detailed psychometric assessments, including IQ testing, are recommended, especially for patients at risk of neuropathic disease (1).

Cardiopulmonary Evaluation: Although rare in children with GD1, cardiopulmonary involvement should be ruled out in symptomatic patients. Risk factors for severe pulmonary hypertension in GD patients include specific genetic variants, family history, and certain health conditions. Assessment may involve chest radiography, CT imaging, electrocardiography, echocardiography, and pulmonary function tests (1, 6).

Routine Monitoring: Monitoring of GD involves regular physical examinations, neurological evaluations, hemoglobin and platelet count measurements, biomarker tracking, and radiological assessments of visceral and skeletal involvement. Additional evaluations may be necessary for associated conditions like anemia, bleeding disorders, hepatomegaly, clonal gammopathies, and skeletal diseases. Neurological and Pulmonary Assessment: Neurological symptoms, including peripheral neuropathy and pulmonary conditions like hypertension and sleep apnea, are also closely monitored (5-8).

Laboratory Evaluation:

The initial laboratory assessment should cover various parameters, including hemoglobin, platelet count, white blood cells, liver function, iron levels, thyroid function, and coagulation. Additionally, measuring specific markers like glucocerebrosidase (GBA1) and chitotriosidase can aid in monitoring disease progression. Serial increases in these markers may indicate a clinical relapse. Biochemical Markers: Key biochemical indicators for monitoring Gaucher's disease (GD) progression include chemokine CCL18/PARC, chitotriosidase, and glucosylsphingosine. These markers are responsive to therapy and aid in deciding when to initiate or adjust treatment. Other markers, such as ACE and acid phosphatase, are initially elevated but less effective in evaluating treatment response. Current research is focused on identifying additional biomarkers for accurate diagnosis and severity assessment (7, 8).

Radiology Assessment:

The primary radiological evaluation for GD should encompass a series of tests to assess liver and spleen size and the severity of skeletal involvement. This assessment helps determine the necessity of enzyme replacement therapy (ERT) and monitors its effectiveness. It typically involves MRI or abdominal ultrasonography to evaluate hepatosplenomegaly, cirrhosis, and fibrosis, and MRI to detect bone marrow infiltration, infarction, and osteonecrosis. MRI is particularly sensitive for identifying marrow infiltration and active bone infarcts, and the Bone Marrow Burden Score is a standard method for grading marrow infiltration. Radiographs of the femora and spine are used to detect asymptomatic skeletal diseases, and DXA scans assess generalized osteopenia (8-10).

Children's Growth:
Based on the Greulich and Pyle method, the assessment of skeletal age in children is crucial for evaluating growth patterns (1).

Functional Health and Well-being:
Children with GD face similar psychosocial challenges as other chronically ill children, impacting their mental health, self-esteem, and academic performance. The Short Form 36 Health Survey (SF-36) is a validated instrument for evaluating the impact of GD on individuals over 14 years of age. Pain severity and quality of life are also monitored regularly (2).

Prognosis: The clinical course of GD1 varies widely, from asymptomatic cases to severe early childhood onset. The progression rate can differ significantly, even among siblings. Regular evaluations are crucial for untreated patients or those refusing treatment. The risk of hematologic malignancies like plasma cell myeloma is higher in GD patients, necessitating specialized care. GD2 and GD3, the neuronopathic forms, have a poorer prognosis with rapid neurological deterioration.

In conclusion, this paper provides a contemporary perspective on Gaucher disease, offering insights into its pathophysiology, clinical management, and the promising therapeutic avenues on the horizon. Gaucher disease continues to intrigue researchers and clinicians alike, and this comprehensive overview aims to contribute to our collective understanding of this complex genetic disorder.

Funding: No funds, grants, or other support was received

Conflicts of interest/Competing interests: No competing interest

References:

1. Louw, V. J., Fraser, I., & Giraldo, P. (2023). Management goals of type 1 Gaucher disease in South Africa: An expert Delphi consensus document on good clinical practice. PloS one, 18(8), e0290401. https://doi.org/10.1371/journal.pone.0290401.
2. Zahran, A. M., Saad, K., Elsayh, K. I., Abdou, M. A. A., Abo-Elgheet, A. M., Eloseily, E. M., Khalaf, S. M., Sror, S., Ahmad, F. A., Elhoufey, A., Ghandour, A., & Osman, N. S. (2022). Upregulation of Cytotoxic T-cells in pediatric patients with Gaucher disease. Scientific reports, 12(1), 4977. https://doi.org/10.1038/s41598-022-08843-4
3. Minervini, G., Franco, R., Marrapodi, M. M., Mehta, V., Fiorillo, L., Badnjević, A., Cervino, G., & Cicciù, M. (2023). Gaucher: A Systematic Review on Oral and Radiological Aspects. Medicina (Kaunas, Lithuania), 59(4), 670. https://doi.org/10.3390/medicina59040670.
4. Pastores, G. M., & Hughes, D. A. (2000). Gaucher Disease. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle.
5. Zahran, A. M., Saad, K., Abdallah, A. M., Gad, E. F., Abdel-Raheem, Y. F., Zahran, Z. A. M., Nagiub Abdelsalam, E. M., Elhoufey, A., Alruwaili, T., Mahmoud, K. H., & Elsayh, K. I. (2021). Dendritic cells and monocyte subsets in children with Gaucher disease. Pediatric research, 90(3), 664–669. https://doi.org/10.1038/s41390-020-01300-w

6. Giuffrida, G., Markovic, U., Condorelli, A., Calafiore, V., Nicolosi, D., Calagna, M., Grasso, S., Ragusa, M. T. V., Gentile, J., & Napolitano, M. (2023). Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review. Orphanet journal of rare diseases, 18(1), 27. https://doi.org/10.1186/s13023-023-02623-7
7. Zahran, A. M., Saad, K., Abo-Elela, M. G., Eloseily, E. M., Gad, E. F., Elgheet, A. M. A., Mahmmoud, R. R., Youssef, M. A. M., Abdelmeguid, M. M., Hawary, B., Darwish, S. F., Elhoufey, A., & Elsayh, K. I. (2019). Down-regulation of Regulatory T-cells in Children With Gaucher Disease Under Enzyme Replacement Therapy. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 25, 1076029619889685. https://doi.org/10.1177/1076029619889685
8. Zahran, A. M., Eltayeb, A. A., Elsayh, K. I., Saad, K., Ahmad, F. A., & Ibrahim, A. I. M. (2017). Activated and Memory T Lymphocytes in Children with Gaucher Disease. Archivum immunologiae et therapiae experimentalis, 65(3), 263–269. https://doi.org/10.1007/s00005-016-0421-y
9. Castillon, G., Chang, S. C., & Moride, Y. (2022). Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review. Journal of clinical medicine, 12(1), 85. https://doi.org/10.3390/jcm12010085
10. Linari, S., & Castaman, G. (2022). Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications. Journal of clinical medicine, 11(23), 6920. https://doi.org/10.3390/jcm11236920.